Everolimus

  • PDF / 170,001 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 32 Downloads / 124 Views

DOWNLOAD

REPORT


1 S

Various toxicities: 8 case reports In a retrospective study of 15 patients, 8 patients (6 men and 2 women) aged 31–67 years were described, who developed mucositis, leukopenia, neutropenia, thrombocytopenia, pneumonia or pancytopenia during treatment with everolimus for thymic carcinoma, thymoma or thymic neoplasm [duration of treatment to reactions onset not stated; not all doses and outcomes stated]. All eight patients were diagnosed with thymic epithelial tumors including thymic carcinoma (n=2), thymic neoplasm (n=1), thymoma (n=5). Four patients had a history of autoimmune disorders including polyarthritis and Good’s syndrome (n=1), enteropathy and neutropenia (n=1), myasthenia gravis (n=1) and autoimmune hemolytic anaemia, red cell aplasia and immunemediated arthritis (n=1). Previously, they all had received various chemotherapies. Subsequently, they started receiving oral everolimus every day. Starting dose of everolimus in three patients ranged between 7.5mg–10mg. Subsequently, they all developed everolimus-related adverse effects which were as follows: grade 3 mucositis (2 Patient), grade 2 leukopenia (1 Patient), grade 3 mucositis and pneumonia (1 Patient), grade 3 neutropenia (1 Patient), grade 3 thrombocytopenia (1 Patient), grade 1 thrombocytopenia (1 Patient), and grade 3 pancytopenia and grade 2 mucositis (1 patient). One patient with grade 3 mucositis had colitis (concurrent condition) and one patient with grade 2 leukopenia had anorexia (concurrent condition). Treatment with everolimus was discontinued in 2 patients and the dose of everolimus was reduced in 5 patients due to treatment related adverse effects. The dose was reduced in 3 patients after 19 days, 6.5 months or 3 weeks. One patient discontinued the everolimus due own preference. The patients responded well to the dose reduction. Subsequently, everolimus was discontinued in 2 patients due to progression of the disease. Hellyer JA, et al. Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer 149: 97-102, Nov 2020. Available from: URL: http://doi.org/10.1016/ 803515519 j.lungcan.2020.09.006

0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 21 Nov 2020 No. 1831